The coming into effect of new legislation governing the conduct of clinical trials in the EU has been delayed again due to difficulties with the development of the underlying IT system, the European Medicines Agency announced on 16 June.
Helsinn Healthcare SA has returned elsiglutide, a treatment for chemotherapy-induced diarrhoea, to its creator, Zealand Pharma A/S, thus ending a partnership agreement to develop the drug further.
Abzena Plc, which provides technology and services to pharmaceutical companies, reported an 89% increase in revenue to £18.7 million for its fiscal year ended 31 March 2017.
A UK medical charity has decided that royalty income from intellectual property that it licensed to the developers of Keytruda, should be reinvested in innovation. The charity, LifeArc, has therefore set up two new funds to support academic research and early-stage biotech companies.
It has been a little more than a year since Medicxi Ventures (UK) LLP was spun out of Index Ventures to provide capital to early life science in Europe. Now, the venture fund has expanded its reach with the launch of a new fund that will finance later stage assets.
Kiadis Pharma NV of the Netherlands has raised €5 million in new funds from a private placement of its shares which will help finance a Phase 3 study of its lead cell therapy for immune reconstitution, which was submitted for review by the European Medicines Agency on 26 April.
Scientists at Imperial College London have determined that pneumococcal bacteria have been able to thwart vaccines because a “hotspot” of rapidly evolving
The term biopsy has traditionally been associated with the examination of tissue from a patient in order to detect the presence of disease. Tissue samples can be taken from the bone marrow, or organs such as the bladder, lung or liver, using procedures of varying complexity from the insertion of a needle into the skin, to surgery.
For the first time, scientists at BioNTech AG have shown that it is possible to instruct an organism to create its own bispecific antibodies capable targeting and killing cancer. The experiment, conducted in mice, was reported in Nature Medicine on 12 June.
Bonesupport Holding AB, a Swedish orthobiologics company, has announced plans to raise SEK 500 million (€51.2 million) on Nasdaq Stockholm in order to expand sales of its bioceramic bone graft substitutes that are used to treat bone infections and trauma.